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Patients with mechanical heart valves have a high
risk of thrombus formation on the valve and
subsequent systemic embolism. These patients there-
fore need to receive life-long oral anticoagulation
(OAC). Despite this treatment, the overall incidence
rate of major thromboembolic complications is still
about 1-2 per 100 patient-years. Additionally, these
patients have an increased risk of bleeding compli-
cations, ranging between l and 7 per 100 patient-
years.
To reduce both types of often very serious complica-
tions, the optimal intensity of anticoagulation needs
to be established. We found a fairly wide optimal
ränge between 2.5 and 4.9 INR (international
normalized raüo) at which the incidence of both
untoward events was minimal. As a target intensity,
we recommend opting for the middle of this ränge
(INR 3.0-4.0), thereby providing a safe margin at
both ends.
In order to further reduce thromboembolic and
bleeding complications, two approaches can be
considered: first of all, the management of OAC
treatment needs to be optimized in order to achieve a
stable therapeutic effect in äs many patients äs
possible. Secondly, patient characteristics need to be
identified that increase the thromboembolic or
bleeding risk. Subsequently, the optimal intensity
may need to be adjusted accordingly, at an
individual level. Possible risk factors for an increased
thromboembolic risk are position and type of the
prosthesis. Age may increase both the risk of





Mechanical heart valve prostheses have a high
thromboembolic potential. This can be partly
attributed to the inorganic material they are made
of, but is also a result of nonphysiological blood flow
patterns around the prosthesis, with areas of
turbulent flow and relative Stagnation. The risk of
thrombus formation on the valve and subsequent
embolism without any antithrombotic treatment
averages about 10% per year [1]. This is in contrast
to patients with biological prostheses whose throm-
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boembolic risk is not considered to be increased
(aller the first 3 months) in the absence of other risk
i'actors such äs atrial fibrillation or an enlarged left
atrium [2]. There is therefore no doubt that patients
with mechanical heart valve proslheses need to
receive life-long oral anticoagulation (OAC), which,
unl'ortunately, is associated with an increased risk of
haemorrhagic complications.
Optimal intensity
Despite the use of OAC, the overall incidence rate of
major thromboembolic complications is still about
1-2 per 100 patient-years [1]. Major bleeding
events ränge between l and 7 per 100 patient-
years [2]. In a follow-up study of 1608 unselected
patients with a mechanical heart valve treated in
regional anticoagulant clinics, we found that the
risk of any major adverse event (all thromboembo-
lism or bleeding combined) was 3.5 per 100 patient-
years [3]. The most feared complication is stroke,
whether it is thromboembolic or haemorrhagic. In
our study, we found an incidence of intracranial
bleeding of 0.5 per 100 patient-years and of cerebral
infarction of 0.7 per 100 patient-years. Seventy-two
per cent of these patients died or suffered lasting
neurological impairment.
For many indications for oral anticoagulant
therapy it has been established that with more
intense anticoagulation, thromboembolism is pro-
gressively prevented, whilst the risk of bleeding
increases [3-6]. Consequently, a level of anti-
coagulation can be found at which both complica-
tions are minimal, i.e. the optimal intensity of OAC.
For mechanical heart valves, we found this Optimum
between 2.5 and 4.9 INR [3]. Within this ränge, the
incidence of all untoward events was about two per
100 patient-years, rising to extreme values below
and above: from an incidence of 7.5 per 100 pa-
tient-years for INR 2.0-2.5, up to an incidence of 27
per 100 patient-years at the very low ränge of
1.0-1.4. At the other end, the incidence of all events
rose steeply again, from 4.8 per 100 patient-years at
INR 5.0-5.5 up to 75 per 100 patient-years at INR-
levels over 6.5 (Fig. 1). Since the risk of any
untoward event hardly varied between an INR of
2.5 and 4.9, we recommend choosing a target
intensity lying in the middle of this ränge (INR















Fig. l INR-specific incidence of al l adverse events (all episodes öl
thromboembolism. all major bleeding episodes and unclassified
stroke). The dotted lines indicate the 95% confidence interval.
(Reproduced wilh permission from N Ilngl ] Med ]99S; 333:
11-17.)
Optimal treatment: further reducing com-
plications
If we want to aim our efforts at further reducing the
number of both thromboembolic and bleeding
complications, two approaches can be considered.
First of all, we can concentrate on the patients who
have INR values below and above the optimal ränge
(and are therefore al high risk of either thromboem-
bolism or bleeding), and question why their treat-
ment apparently is inadequate. Secondly, we must
realize that, although the risk is lowest wilhin the
optimal ränge, the absolute number of events that
occurs here is still considerable (since the majority of
the palients are within this ränge most of the üme).
Therefore, we should try lo assess what other factors
contribute to the occurrence of slroke, despite the
fact that OAC treatment is adequate.
Improving anticoagulant trcalment
Oral anticoagulant treatment is achieved with
coumarin derivatives, vitamin K-antagonist drugs
which impair thrombus formation to an cxtent that
depends on the coumarin dose. However, large
discrepancies exist in dose and anticoagulant
response between subjects. Besides, these variations
also occur in the same patient during long-term
treatment. As a consequence, the intensity of the
anticoagulant treatment needs to be measured
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regularly and, if iiecessary, the dosage adjusted. The
way this is organized differs largely belween
counlries; in the Netherlands specialized anticoagu-
laüon clinics have been emerging since the 1950s,
and countries such äs Italy, Canada and the United
States have since followed. Monitoring by these
clinics clearly improves the quality of care [7], Still,
even within such a setting, only about 60-70% of
the intensity measurements are found to be within
the target ränge, about 20-30% are below and 10%
above the upper ränge [3, 8], Many factors may
contribute to this variability, such äs changes in diel
(availability of vitamin K) [9], poor patient com-
pliance [10], comedication [11] and intercurrent
diseases. Possible strategies to improve the amount
of time spent within the target zone were recently
described. Weibert et al. showed that administering
2.5 mg of oral vitamin K rapidly corrects excessive
anticoagulation (INR > 5.0) without inducing re-
sistance lo further anticoagulalion [12], Ansell et al.
proposed introducing patient self-management of
their OAC dose, and showed in their study that this
can be a successful approach [13]. Van der Meer
et al. showed in a pilot Intervention study that it is
possible to improve compliance by special attention
and devices [10],
Subgroups with different risk profiles
-Ris/< jactors for thromboembolism
Associated with the prosthesis. All currently
available types can be classified into three broad
categories with largely different flow characteristics
[14]: the caged ball types (Starr-Edwards); single-
tilting disk valves (Björk-Shiley, Sorin, Medtronic
Hall, Omnicarbon); bileaflet valves (St Jude, Duro-
Medics, CarboMedics). Only one study has compared
directly in a randomized design possible differences
in thromboembolic risk between these valve types
[15]. In this study a higher thromboembolic risk was
found in patients with a bileaflet model (Edwards-
Duromedics) and in patients with a Medtronic Hall
valve, compared to Björk-Shiley valves. However, it
has been debated whether these discrepancies
should be attributed to different thrombogenicity
[16]. In a meta-analysis of 46 observational studies
on thromboembolic complicaüons in patients with
mechanical heart valves, we found a higher risk of
embolic complicaüons in patients with a caged-ball
valve [1], Compared to patients with a caged ball
valve, the incidence of total thromboembolism was
30% lower for patients wilh a tilting disk valve (RR
0.7 (95% CI 0.5-0.9)), and 50% lower for patienls
with a bileaflet valve (RR 0.5 (95% CI 0.4-0.7)). In
the cohort study of 1608 patients with mechanical
heart valves, we also found a clearly higher risk of
thromboembolism in patients with caged-ball valves,
which was independent of other factors such äs age
or position of the valve. An incidence of 0.5 per
100 patient-years was found for the bileaflet valves,
of 0.7 per 100 patient-years for the tilting disk
valves, and of 2.5 per 100 patient-years for the
caged-ball valves [3]. The position of the prosthesis
(mitral, aortic or both) also influences the throm-
boembolic risk. The results of the meta-analysis
showed that the risk of major embolism was about
doubled in patients with a mitral prosthesis [1]. In
the cohort-study, we found similar differences. In
patients with an aortic prosthesis the incidence of
thromboembolism was 0.5 per 100 patient-years, in
patients with a mitral valve it was 0.9 per
100 patient-years, and 1.2 per 100 patient-years
in those with both an aortic and a mitral valve [3].
Associated with other cardiac disease. When
effective mechanical atrial activity is impaired, blood
stasis may enhance the development of atrial
thrombi and thus increase the risk of systemic
embolism. This may occur in atrial fibrillation and
left atrial enlargement. It is difficult to assess to what
extent the increased risk of a mitral prosthesis can be
explained by atrial abnormaliües or vice versa, since
they are strongly associated. Burchfiel et al. found a
threefold higher incidence of systemic thromboem-
bolism in patients with an enlarged left atrial
dimension [17]. However, this effect was entirely
explained by the location of the prosthesis (mitral
versus aortic), when this was taken into account in
a multivariate analysis [17]. Contradictory results
have been published on atrial fibrillation. Burchfiel
ei al. found an independent increased risk in these
patients, whilst Butchart et al. did not [18].
Other risk factors. It is not clear to what extent
established risk factors for ischaemic stroke in the
general population have an additional effect on the
high risk already present in artificial heart valve
patients. This is probably caused by a lack of
sufficient numbers of stroke patients within study
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groups to allow for statistically solid conclusions on
subgroups. We f'ound an effect of age on the risk of
thromboembolism [3]. Of all 45 events, only one
occurred in a patient younger than 50 (0.1 per
100 patient-years), and this risk rose to 0.8 per
100 patient-years in patients between 50 and 70
and up to 1.1 per 100 patient-years in patients older
than 70. Butchart et al. found hypertension to be a
strong risk factor in patients with aortic valve
replacements, äs well äs smoking [18]. Cortelazzo
et al reported an increased risk of thromboembolism
in patients who had a history of such a complication
[7l
Risk factors for bleeding
There have been many reports on risk factors for
bleeding in anticoagulated patients, although most
have done so only for total groups of patients
anticoagulated for a variety of indications. Unfortu-
nately, these studies create some confusion about
risk factors for bleeding. First of all, conflicting
results have been reported about the effect of age on
bleeding risk. About an equal number of papers have
described how elderly patients are at higher risk for
haemorrhagic complications [3, 19-23], äs have
failed to find such an association [7, 24-27].
Contradictory findings have also been reported on
the effect of hypertension. Most authors did not find
a clear association [7, 26, 28, 29]. Only Launbjerg
et al. described a slightly increased bleeding risk in
patients with hypertension [21]. Cortelazzo et al.
found increased bleeding risk in patients who had
had a previous haemorrhage [7]. Landefeld et al.
also found that a history of gastrointestinal bleeding
increased the risk of major bleeding about threefold
[20]. This effect has not been described by other
authors. They also described a similar influence of
the presence of a serious comorbid condition such äs
recent myocardial infarction, renal insufficiency or
severe anaemia. Fihn et al. reported only a slightly
increased effect of the presence of three or more
comorbid conditions [29]. Gitter et al. found the
presence of malignancy to be associated with
bleeding risk [26].
On the whole, these results are quite contra-
dictory. An explanation for the discrepancies is
difficult to provide. Several mechanisms may be
plausible äs described by Beyth & Landefeld [30], for
example a lack of statistical power to detect a
difference due to a limited number of events in the
subgroups. Furthermore, it could be due to selection
bias, since in a trial setting äs well äs in an
observational study, patients with perceived high
bleeding may be withheld from treatment with OAC.
Optimal intensity for subgroups
When it is known that a certain risk factor increases
the thromboembolic or the bleeding risk, it needs to
be assessed how this affects the optimal anti-
coagulation level. Two scenarios may be considered,
either the incidence rate of the adverse event is
increased to the same extent at every INR level (in
which case the optimal level does not change), or
the risk increases only at lower intensities for
subgroups with increased risk of thromboembolism,
and only at higher intensities for subgroups with
increased risk of bleeding. In our cohort study we
investigated if and how the optimal level changed
according to age, valve position and valve type [3].
The results showed that when an increased throm-
boembolic risk had been established for a subgroup
(e.g. mitral versus aortic valve), this was associated
with a higher incidence of thromboembolism only at
the lower INR levels (2-3 INR), in other words, the
optimal level was narrowed on the left side of the
curve. The same applied for the only subgroup in
which an increased bleeding risk was found (age
older than 70), in whom the incidence of bleeding
was increased only at higher INRs (4-5 INR),
compared to the younger age groups. In short, the
difference between subgroups manifested itself only
at the extremes of the optimal level. If this finding is
confirmed in other studies, it may imply that the
optimal level should indeed be adapted according to
an individual's characteristics.
Adding aspirin
Some recent research has been aimed at further
reducing thromboembolic complications by adding
aspirin to the anticoagulant treatment [31, 32].
Turpie et al. added low-dose aspirin (100 mg) to
warfarin treatment (INR 3.0-4.5) and found a
reduction of the embolic rates in the aspirin group,
which was associated with an increased risk of
major bleeding of 8.5 per 100 patient-years [31].
Meschengieser et al. compared 100 mg aspirin
added to less intense warfarin treatment (INR
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2.5-3.5), to warfarin alone (INR 3.5-4.5) and found
a similar thromboembolic risk in both arms, whilst
the bleeding risk was higher in the warfarin alone
group [32]. These two trials offer interesüng
Information but can not yet be considered äs
sufficient basis for recommending combinaüon
treatment (see below about the Information gained
from aetiologic and pragmatic studies).
Further research
More trials have recently been published comparing
different intensity schemes [33, 34]. The ARE V A
trial compared moderate anticoagulation (INR
2.0-3.0) to the usual regimen of INR 3.0-4.5. In
this study a similar risk in thromboembolic events
was found in both arms, whereas the bleeding risk
was higher in the high intensity group [33]. Pengo
et al. compared treatment with a target INR of 3.0 to
a target INR of 4.0 and found similar results [34].
The question is what these trials (both the aspirin
and the different regimes studies) contribute to our
ultimate aim, i.e. reducing complications in these
patients. Two types of studies can be distinguished in
this context: (i) aetiological studies, in which
research is aimed at detecting factors that determine
the occurrence of an event; (ii) pragmatic studies, in
which we want to assess the optimal practical
strategy to actually decrease the risks. At an
aetiological level, we feel that the effect of intensity
of OAC treatment has been sufficiently studied [3].
In our study we calculated incidence rates of adverse
events by taking the ratio of the number of events
that actually occurred at a certain INR and the total
number of patient-years that this INR had been
achieved by the total patient population. They were
therefore independent of the target level and purely
represented the risk of an event when a certain INR
is achieved. However, the patients in this study
consisted of a large, heterogeneous group, so these
results can only be applied to this group äs a whole.
Therefore, more research is needed to identify
patient characteristics that increase or decrease
either the thromboembolic or the bleeding risk and
how they interact with OAC treatment. At a
pragmatic level, for any other type of medication
the trial approach would be the most informative in
finding out the best regimen. However, since the
management of anticoagulant treatment is so
complicated and dependent on so many factors, it
is very difficult to apply results from one centre to
the other. In the Turpie trial, for example, the
intensity of the anticoagulant control was within the
target ränge only 40% of the time [31]. Even though
they found a reduction of the risk of embolism when
aspirin was added, it seems very unlikely that adding
aspirin to anticoagulant treatment in the Nether-
lands would have the same effect, since the risk of
complications there is already lower, thanks to well
controlled OAC treatment. Another problem with
trials in this field is the oversimplified comparison
between bleeding and thromboembolic events. A
thromboembolic complication is usually much more
severe than a bleeding, especially in terms of
permanent disability. The AREVA trial, for example,
was stopped when the bleeding risk was significantly
higher in the high than in the low intensity arm,
whereas the thromboembolism risk was equal in
both [33]. However, this was only due to an increase
in minor haemorrhagic events, whilst the risk of
major bleeding was not different. Minor events were
defmed äs 'all non-major bleeding', which hardly
seems comparable to thromboembolic events. Since
bleeding (especially defmed like this) is much more
common than thromboembolism, this inevitably
results in a Situation where any possible difference
in thromboembolic rate can not be detected.
Pragmatically, therefore, instead of performing an
endless series of trials comparing different intensi-
ties, it is probably more efficient to establish ways of
improving OAC treatment at a local level and to find
ways to keep äs many patients äs possible within the
optimal ränge.
Conclusion
Unfortunately, patients with prosthetic heart valves
need to be treated with OAC for the rest of their lives.
Cumulatively, they have a considerable risk of 'ever'
experiencing a serious thromboembolic or bleeding
complication. We need to conünue searching for
ways to prevent these. Further research should be
aimed at finding ways to optimize the management
of OAC treatment and at identifying patient char-
acteristics that increase the thromboembolic or
bleeding risk.
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